GlassScriptPhysician profile
Ghiulser Selim
NPI 1245203645
$2,016.36
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $404 · 2021: $216 · 2022: $955 · 2023: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.99 | 2019-2023 | Spravato |
| Alkermes, INC. | $139.97 | 2021-2023 | Aristada, Lybalvi |
| Sanofi-Aventis U.S. LLC | $128.75 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $112.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.12 | 2022 | |
| Abbvie INC. | $111.77 | 2019-2022 | |
| Novo Nordisk INC | $99.78 | 2019-2023 | Ozempic |
| Glaxosmithkline, LLC. | $95.98 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $84.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.39 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.83 | 2022 | |
| Pfizer INC. | $65.61 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.42 | 2022-2023 | |
| Amgen INC. | $60.32 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $58.82 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.91 | 2020-2022 | |
| Amarin Pharma, INC. | $43.30 | 2019-2020 | |
| Allergan, INC. | $38.38 | 2020 | |
| Astellas Pharma US INC | $36.99 | 2019 | |
| Abbott Laboratories | $36.91 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.65 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $34.70 | 2022 | |
| Lilly USA, LLC | $30.32 | 2020-2021 | |
| Phadia US INC. | $24.68 | 2019-2020 | |
| Mylan Specialty L.P. | $24.43 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.67 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $22.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.98 | 2022 | |
| Axsome Therapeutics, INC. | $20.75 | 2023 | Sunosi |
| Daiichi Sankyo INC. | $17.46 | 2019 | |
| Currax Pharmaceuticals LLC | $14.86 | 2021 | |
| Lundbeck LLC | $14.49 | 2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $12.84 | 2020 | |
| Brainsway USA INC | $12.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghiulser Selim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.